58377-44-9

Basic information

• Product Name: tert-butyl N-methoxycarbamate
• Synonyms: tert-butyl N-methoxycarbamate;tert-Butyl methoxycarbamate;N-Boc-O-methylhydroxylamine
• CAS NO: 58377-44-9
• Molecular Formula: C₆H₁₃NO₃
• Molecular Weight: 147.17232
• Mol File: 58377-44-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 83-84 °C(Press: 10 Torr)
• Appearance: /
• Density: 1.006±0.06 g/cm3(Predicted)
• CAS DataBase Reference: tert-butyl N-methoxycarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-methoxycarbamate(58377-44-9)
• EPA Substance Registry System: tert-butyl N-methoxycarbamate(58377-44-9)

Safety Data

• Hazardous Substances Data: 58377-44-9(Hazardous Substances Data)

Usage

Uses

N-Boc-O-methyl Hydroxylamine is used to prepare (pyridinylmethylamino)furanones as insecticides.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 593-56-6 N-methoxylamine hydrochloride 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 74-88-4 methyl iodide 
• 75-65-0 tert-butyl alcohol 
• 1516-56-9 azidoformiate de methyle 

Downstream Products

• 76570-50-8 N-tert-butoxycarbonyl-N-phenyl-O-methylhydroxylamine 
• 1315566-31-4 C₁₅H₂₀ClNO₃ 
• 1347753-75-6 C₁₆H₂₃NO₄ 
• 1315566-39-2 C₁₆H₂₃NO₄ 
• 1347753-73-4 C₁₆H₂₃NO₄ 
• 1315566-37-0 C₁₆H₂₃NO₄ 
• 1315566-34-7 C₁₆H₂₃NO₄ 
• 1315566-30-3 C₁₅H₂₀FNO₃ 
• 1315566-33-6 C₁₆H₂₃NO₃ 
• 1347753-70-1 C₁₅H₂₀BrNO₃ 
• 1315566-32-5 C₁₅H₂₀BrNO₃ 
• 1347753-71-2 C₁₅H₂₀ClNO₃ 
• 1315566-35-8 C₁₅H₂₀ClNO₃ 
• 1347753-72-3 C₁₅H₂₀BrNO₃ 

Relevant articles and documents

Asymmetric Phase-Transfer Catalytic aza-Michael Addition to Cyclic Enone: Highly Enantioselective and Diastereoselective Synthesis of Cyclic 1,3-Aminoalcohols

The highly enantioselective aza-Michael reaction of tert-butyl β-naphthylmethoxycarbamate to cyclic enones has been accomplished by using a new cinchona alkaloid derived C(9)-urea ammonium catalyst under phase-transfer catalysis conditions with up to 98% ee at 0 °C. The resulting aza-Michael adducts can be converted to versatile intermediates by selective deprotection and the cyclic 1,3-aminoalcohols by diastereoselective reduction with up to 32:1, which have been widely used as important pharmacophores in pharmaceutical development.

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.